Months in­to boom­ing acute mi­graine launch, Bio­haven chas­es pre­ven­tion with oral CGRP med Nurtec ODT

In the sud­den­ly bustling mar­ket for CGRP acute mi­graine fight­ers, Bio­haven has tout­ed its Nurtec ODT as an ob­vi­ous choice for pa­tients with its fast dis­solv­ing oral for­mu­la­tion. De­spite hit­ting the oral mar­ket sec­ond, Nurtec is keep­ing pace with its im­me­di­ate ri­val and is an­gling for even big­ger fish in pre­ven­tion.

In Phase III da­ta pub­lished Tues­day in The Lancet, Bio­haven’s Nurtec cut pa­tient’s av­er­age mi­graine days by 4.3 per month com­pared with place­bo and sliced the num­ber of mod­er­ate-to-se­vere mi­graines per month by more than 50%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER